RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
XSpray Pharma AB (publ) Stock

XSpray Pharma AB (publ) ROCE 2025

XSpray Pharma AB (publ) ROCE

-0.26

Ticker

XSPRAY.ST

ISIN

SE0009973563

WKN

A2H48J

In 2025, XSpray Pharma AB (publ)'s return on capital employed (ROCE) was -0.26, a 25.05% increase from the -0.21 ROCE in the previous year.

XSpray Pharma AB (publ) Aktienanalyse

What does XSpray Pharma AB (publ) do?

XSpray Pharma AB (publ) was founded in Sweden in 2003 and is headquartered in Stockholm. The company specializes in the development and manufacturing of pharmaceutical products tailored to the needs of patients with unique medical challenges. The business model of XSpray Pharma is based on patenting and selling its MicroSpray technology platform, which allows drugs to be transformed into a microfine spray form, thereby improving bioavailability, duration, and intensity of action. The company has three main divisions: - The first division is contract research, where XSpray Pharma licenses its technology platform to other pharmaceutical companies and assists them in drug development. - The second division is the development of its own medications, where XSpray Pharma develops innovative therapies for rare diseases. The company works closely with patient organizations, doctors, and scientists to better understand patient needs and address their medical challenges. - The third division is partnership with other pharmaceutical companies, where XSpray Pharma contributes its technology platform and drug development expertise to collaboratively develop and market innovative therapies. One of XSpray Pharma's key products is APT-1011, a spray for severe nausea and vomiting in cancer patients that acts quickly and effectively due to its microfine nature. It has received European approval (EMA) and is being submitted in the US in collaboration with US pharmaceutical company RedHill Biopharma. Another important product is APT-1026, a spray for the treatment of hypersensitivity reactions. It is currently in development and is intended to help patients with various types of hypersensitivity reactions in the future. In addition, XSpray Pharma has several patented technology platforms and a wide range of drug candidates in the pipeline. The company works closely with its partners to leverage its technology and expertise in drug development to jointly create innovative therapies for patients. In recent years, XSpray Pharma has received several awards and recognitions for its innovative technology and drug development, including the Swedish Pharma Prize and the European Mediscience Award. In summary, XSpray Pharma is an innovative pharmaceutical company specializing in the development of drugs for patients with unique medical challenges. The company has utilized its MicroSpray technology platform and drug development expertise to develop a wide range of drug candidates in the pipeline aimed at improving the lives of patients. XSpray Pharma AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling XSpray Pharma AB (publ)'s Return on Capital Employed (ROCE)

XSpray Pharma AB (publ)'s Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing XSpray Pharma AB (publ)'s ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

XSpray Pharma AB (publ)'s ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in XSpray Pharma AB (publ)’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about XSpray Pharma AB (publ) stock

What is the ROCE (Return on Capital Employed) of XSpray Pharma AB (publ) this year?

The ROCE of XSpray Pharma AB (publ) is -0.26 undefined this year.

How has the ROCE (Return on Capital Employed) of XSpray Pharma AB (publ) developed compared to the previous year?

The ROCE of XSpray Pharma AB (publ) has increased by 25.05% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of XSpray Pharma AB (publ)?

A high Return on Capital Employed (ROCE) indicates that XSpray Pharma AB (publ) has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of XSpray Pharma AB (publ)?

A low ROCE (Return on Capital Employed) can indicate that XSpray Pharma AB (publ) has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from XSpray Pharma AB (publ) impact the company?

An increase in the ROCE of XSpray Pharma AB (publ) can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of XSpray Pharma AB (publ) affect the company?

A decrease in ROCE of XSpray Pharma AB (publ) can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of XSpray Pharma AB (publ)?

Some factors that can affect XSpray Pharma AB (publ)'s ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of XSpray Pharma AB (publ) so important for investors?

The ROCE of XSpray Pharma AB (publ) is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can XSpray Pharma AB (publ) take to improve the ROCE?

To improve the ROCE, XSpray Pharma AB (publ) can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does XSpray Pharma AB (publ) pay?

Over the past 12 months, XSpray Pharma AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XSpray Pharma AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of XSpray Pharma AB (publ)?

The current dividend yield of XSpray Pharma AB (publ) is .

When does XSpray Pharma AB (publ) pay dividends?

XSpray Pharma AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) paid dividends every year for the past 0 years.

What is the dividend of XSpray Pharma AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is XSpray Pharma AB (publ) located?

XSpray Pharma AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von XSpray Pharma AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XSpray Pharma AB (publ) from 1/8/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did XSpray Pharma AB (publ) pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of XSpray Pharma AB (publ) in the year 2024?

In the year 2024, XSpray Pharma AB (publ) distributed 0 SEK as dividends.

In which currency does XSpray Pharma AB (publ) pay out the dividend?

The dividends of XSpray Pharma AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von XSpray Pharma AB (publ)

Our stock analysis for XSpray Pharma AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XSpray Pharma AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.